# Regeneron Announces $270 Million Extension for U.S. Ebola Treatment Supply

The BARDA agreement calls for additional Inmazeb deliveries through 2031, according to the company.

By Will Langan | 24X7 News
Published: 2026-10-27T03:04:17.173Z
Updated: 2026-10-27T03:04:17.173Z
Section: Health
Format: News
Canonical: https://24x7news.us/articles/regeneron-barda-inmazeb-ebola-supply-extension-2026

Launch Catch-Up — Agreement Extension Announced October 26, 2026

Regeneron said October 26 that it extended a federal supply agreement for Inmazeb, its three-antibody treatment for Ebola disease caused by Orthoebolavirus zairense.

The company expects to provide additional doses to the U.S. government through 2031 and receive approximately $270 million. The extension builds on a 2020 procurement agreement with the Biomedical Advanced Research and Development Authority, or BARDA, within the Department of Health and Human Services.

The announced value covers expected deliveries and payments over several years. It does not mean all doses have already been delivered or the full amount has been paid.

Inmazeb’s FDA approval dates to 2020. The supply extension is a preparedness procurement announcement, not a new drug approval.

Regeneron separately described research involving one antibody component against Bundibugyo virus. That investigational work is distinct from Inmazeb’s approved indication for Orthoebolavirus zairense; efficacy against other virus species has not been established for Inmazeb.

Sources
Regeneron — October 26 agreement announcement: https://investor.regeneron.com/news-releases/news-release-details/regeneron-extends-agreement-barda-provide-additional-supply

## Sources
- Regeneron — October 26 BARDA agreement extension: https://investor.regeneron.com/news-releases/news-release-details/regeneron-extends-agreement-barda-provide-additional-supply